CU22584A1 - Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis - Google Patents

Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Info

Publication number
CU22584A1
CU22584A1 CU1995120A CU1995120A CU22584A1 CU 22584 A1 CU22584 A1 CU 22584A1 CU 1995120 A CU1995120 A CU 1995120A CU 1995120 A CU1995120 A CU 1995120A CU 22584 A1 CU22584 A1 CU 22584A1
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
monoclonal antibody
recognizes
psoriasis
compositions containing
Prior art date
Application number
CU1995120A
Other languages
English (en)
Inventor
Blazquez Patricia Sierra
Valladares Josefa Lombardero
Casimiro Jose Enrique Montero
Bravo Blanca Rosa Tormo
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU1995120A priority Critical patent/CU22584A1/es
Priority to US08/875,674 priority patent/US6572857B1/en
Priority to CA002210751A priority patent/CA2210751C/en
Priority to ES96939805T priority patent/ES2231826T3/es
Priority to KR1019970704893A priority patent/KR100533854B1/ko
Priority to JP51926797A priority patent/JP4113929B2/ja
Priority to DK96939805T priority patent/DK0807125T3/da
Priority to PCT/CU1996/000004 priority patent/WO1997019111A2/es
Priority to PT96939805T priority patent/PT807125E/pt
Priority to AT96939805T priority patent/ATE280783T1/de
Priority to DE69633717T priority patent/DE69633717T2/de
Priority to BRPI9607171A priority patent/BRPI9607171B1/pt
Priority to CNB96192098XA priority patent/CN1222540C/zh
Priority to AU76905/96A priority patent/AU722882B2/en
Priority to EP96939805A priority patent/EP0807125B1/en
Priority to MXPA/A/1997/005445A priority patent/MXPA97005445A/es
Publication of CU22584A1 publication Critical patent/CU22584A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con la rama de la Inmunología y en particular con la obtención de composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario CD6. De acuerdo con lo expuesto, el objeto de esta invención es proporcionar composiciones farmacéuticas que contengan un anticuerpo monoclonal anti CD6 para el diagnóstico y tratamiento de lesiones cutáneas de la Psoriasis Vulgar. La esencia de la invención consiste en aplicar un anticuerpo monoclonal que reconoce el antígeno CD&, obtener composiciones farmacéuticas que contengan este anticuerpo y sean capaces de lograr una efectividad clínica e histológica en pacientes con las diferentes formas clínicas de la Psoriasis. El campo de aplicación de la presente invención se extiende a la Dermatología.
CU1995120A 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis CU22584A1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US08/875,674 US6572857B1 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses
CA002210751A CA2210751C (en) 1995-11-17 1996-11-18 Anti-cd6 monoclonal antibodies and their uses
ES96939805T ES2231826T3 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
KR1019970704893A KR100533854B1 (ko) 1995-11-17 1996-11-18 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물
JP51926797A JP4113929B2 (ja) 1995-11-17 1996-11-18 アンチｃｄ６モノクロナール抗体とその利用
DK96939805T DK0807125T3 (da) 1995-11-17 1996-11-18 Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones
PT96939805T PT807125E (pt) 1995-11-17 1996-11-18 Anticorpos monoclonais anti-cd6 para o tratamento e diagnose da psoriase
AT96939805T ATE280783T1 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE69633717T DE69633717T2 (de) 1995-11-17 1996-11-18 Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
BRPI9607171A BRPI9607171B1 (pt) 1995-11-17 1996-11-18 anticorpo monoclonal anti-cd6 humano, usos dos mesmos para o diagnóstico in vitro de psoríase, composição farmacêutica e reagente contendo o dito anticorpo
CNB96192098XA CN1222540C (zh) 1995-11-17 1996-11-18 抗cd6的单克隆抗体和它们的用途
AU76905/96A AU722882B2 (en) 1995-11-17 1996-11-18 Anti-CD6 monoclonal antibodies and their uses
EP96939805A EP0807125B1 (en) 1995-11-17 1996-11-18 Monoclonal antibodies anti-cd6 for the treatment and diagnosis of psoriasis
MXPA/A/1997/005445A MXPA97005445A (es) 1995-11-17 1997-07-17 Anticuerpos monoclonales anti-cd6 y sus usos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Publications (1)

Publication Number Publication Date
CU22584A1 true CU22584A1 (es) 1999-11-03

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis

Country Status (15)

Country Link
US (1) US6572857B1 (es)
EP (1) EP0807125B1 (es)
JP (1) JP4113929B2 (es)
KR (1) KR100533854B1 (es)
CN (1) CN1222540C (es)
AT (1) ATE280783T1 (es)
AU (1) AU722882B2 (es)
BR (1) BRPI9607171B1 (es)
CA (1) CA2210751C (es)
CU (1) CU22584A1 (es)
DE (1) DE69633717T2 (es)
DK (1) DK0807125T3 (es)
ES (1) ES2231826T3 (es)
PT (1) PT807125E (es)
WO (1) WO1997019111A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054316A1 (zh) * 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20040208890A1 (en) 2003-02-24 2004-10-21 Institut Pasteur Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
EP2119453B1 (en) * 2006-12-26 2015-05-20 Centro de Inmunolgía Molecular Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of b-chronic lymphocytic leukaemia
US20100092423A1 (en) 2006-12-26 2010-04-15 Centro De Inmunolgía Molecular Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
HUE031207T2 (hu) 2008-01-11 2017-07-28 Adheron Therapeutics Inc Cadherin-11 EC1 domén elleni antitestek gyulladásos ízületi rendellenességek kezeléséhez
US8524233B2 (en) * 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
CA2805112A1 (en) * 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103782173B (zh) 2011-07-01 2018-07-13 贝克曼考尔特公司 调节t细胞和识别、获得、以及用于治疗基于免疫的紊乱的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PT3024485T (pt) 2013-07-23 2021-01-25 Biocon Ltd Utilização de um parceiro de ligação de cd6 e método baseado no mesmo
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
MX2020008916A (es) 2018-02-27 2021-02-15 Equillium Inc Anticuerpos anti cd6 para el tratamiento del asma grave.
JP7376564B2 (ja) 2018-06-29 2023-11-08 シティ・オブ・ホープ 特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体
JP2022521973A (ja) 2019-02-26 2022-04-13 エクイリウム，インコーポレイテッド 抗ｃｄ６抗体組成物およびループスを処置するための方法
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
KR20240055093A (ko) 2021-09-08 2024-04-26 센트로 데 인뮤놀러지아 모레큘러 과다 염증 반응으로 인한 세포 및 장기 손상 예방을 위한 항-cd6 단일클론항체의 용도
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726912A4 (en) * 1993-11-02 2000-08-23 Univ Duke Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Also Published As

Publication number Publication date
PT807125E (pt) 2005-03-31
CN1175957A (zh) 1998-03-11
WO1997019111A2 (es) 1997-05-29
ATE280783T1 (de) 2004-11-15
EP0807125A2 (en) 1997-11-19
JP4113929B2 (ja) 2008-07-09
DE69633717T2 (de) 2006-02-02
BRPI9607171B1 (pt) 2016-07-19
KR19980701502A (ko) 1998-05-15
EP0807125B1 (en) 2004-10-27
JPH11506017A (ja) 1999-06-02
CA2210751A1 (en) 1997-05-29
ES2231826T3 (es) 2005-05-16
KR100533854B1 (ko) 2006-09-20
AU722882B2 (en) 2000-08-10
CN1222540C (zh) 2005-10-12
CA2210751C (en) 2007-01-30
BR9607171A (pt) 1997-11-11
DK0807125T3 (da) 2005-03-14
AU7690596A (en) 1997-06-11
MX9705445A (es) 1998-06-30
WO1997019111A3 (es) 1998-02-12
US6572857B1 (en) 2003-06-03
DE69633717D1 (de) 2004-12-02

Similar Documents

Publication Publication Date Title
CU22584A1 (es) Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CU23251A3 (es) Formulaciones liquidas estables de toxina botulinica
FR2810539B1 (fr) Procede et dispositif de traitement,notamment de maquillage, de coloration ou de soin cosmetique,de parties ou de la totalite du corps humain ou animal
Van Praag et al. Determination of the photoprotective efficacy of a topical sunscreen against UVB-induced DNA damage in human epidermis
ES2060310T3 (es) Utilizacion de la n-miristoil-(s)-fenilalanina para la obtencion de medicamentos destinados al tratamiento de enfermedades que hacen intervenir la miristoilacion.
MX9801596A (es) Composiciones aliviadoras del prurito, cosmeticas y farmaceuticas o ambas.
UY27242A1 (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diasnostico y tratamiento de tumores
Nestor et al. Efficacy and tolerability of a combined 445nm and 630nm over-the-counter light therapy mask with and without topical salicylic acid versus topical benzoyl peroxide for the treatment of mild-to-moderate acne vulgaris
Mostafa et al. Modulation of autophagy, apoptosis and oxidative stress: A clue for repurposing metformin in photoaging
Lehmann Photodermatoses
Rongioletti et al. Erosive pustular dermatosis of the scalp induced by ingenol mebutate.
DK0709097T3 (da) Anti-Fas antistof mod reumatiske sygdomme
Giovinazzo et al. Photoallergic contact dermatitis to musk ambrette: histopathologic features of photobiologic reactions observed in a persistent light reactor
Lamberg Symptomatic pitted keratolysis
AR004355A1 (es) Anticuerpos monoclonales anti-cd6 y sus usos.
ES2161987T3 (es) Parche/pelicula radioactiva y procedimiento para la preparacion de la misma.
Jiyad et al. Handbook of Skin Disease Management
BR9504089A (pt) Agente para o tratamento ou cuidado de pele irritada ou inflamada e aplicação
Young et al. Functional and morphological changes in pig skin after single or fractionated doses of X rays
Eber et al. Photodynamic therapy
Yadav et al. Tattoo for camouflage: A new cause of tattoo regret
Willis Photosensitivity.
Poh-Fitzpatrick The biologic actions of solar radiation on skin with a note on sunscreens
Basdew et al. Adjunctive treatment of keloids: comparison of photodynamic therapy with brachytherapy
Van et al. Efficacy of He-Ne Laser in Combination with Topical Clindamycin in the Treatment of Acne Vulgaris (AV)